Literature DB >> 11937010

Current and future strategies for combined-modality therapy in pancreatic cancer.

Andrew H Ko1, Margaret A Tempero.   

Abstract

Treatment of pancreatic cancer remains a challenging task that often requires a multidisciplinary approach to confer optimal response and, ideally, maximize survival. A combination of locoregional approaches such as surgery and radiotherapy, along with systemic therapies for eradication of micrometastases, should be considered both for patients who are operative candidates and for those with locally advanced, unresectable disease. How best to combine these modalities in terms of schedule, timing, and choice of agents is a question that continues to be actively investigated. Some of these data are equivocal or conflicting; thus standards of care for combined-modality treatment have not been uniformly accepted to date. This article provides an overview of combined-modality therapy, focusing on the major studies that have guided our current approach to the treatment of pancreatic cancer and examining new strategies that are likely to improve outcomes and survival for patients in the future.

Entities:  

Mesh:

Year:  2002        PMID: 11937010     DOI: 10.1007/s11912-002-0017-z

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  52 in total

1.  Extended radical resection of cancer of the pancreas with intraoperative radiotherapy.

Authors:  T Hiraoka
Journal:  Baillieres Clin Gastroenterol       Date:  1990-12

2.  High-dose local irradiation plus prophylactic hepatic irradiation and chemotherapy for inoperable adenocarcinoma of the pancreas. A preliminary report of a multi-institutional trial (Radiation Therapy Oncology Group Protocol 8801).

Authors:  R Komaki; S Wadler; T Peters; R W Byhardt; S Order; M J Gallagher; A Herskovic; J Pederson
Journal:  Cancer       Date:  1992-06-01       Impact factor: 6.860

3.  Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.

Authors:  J P Neoptolemos; J A Dunn; D D Stocken; J Almond; K Link; H Beger; C Bassi; M Falconi; P Pederzoli; C Dervenis; L Fernandez-Cruz; F Lacaine; A Pap; D Spooner; D J Kerr; H Friess; M W Büchler
Journal:  Lancet       Date:  2001-11-10       Impact factor: 79.321

4.  Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.

Authors:  J H Klinkenbijl; J Jeekel; T Sahmoud; R van Pel; M L Couvreur; C H Veenhof; J P Arnaud; D G Gonzalez; L T de Wit; A Hennipman; J Wils
Journal:  Ann Surg       Date:  1999-12       Impact factor: 12.969

5.  Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.

Authors:  T M Breslin; K R Hess; D B Harbison; M E Jean; K R Cleary; A P Dackiw; R A Wolff; J L Abbruzzese; N A Janjan; C H Crane; J N Vauthey; J E Lee; P W Pisters; D B Evans
Journal:  Ann Surg Oncol       Date:  2001-03       Impact factor: 5.344

6.  Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma.

Authors:  P A Philip; M M Zalupski; V K Vaitkevicius; P Arlauskas; R Chaplen; L K Heilbrun; V Adsay; D Weaver; A F Shields
Journal:  Cancer       Date:  2001-08-01       Impact factor: 6.860

7.  Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer.

Authors:  V K Mehta; G A Fisher; J M Ford; H A Oberhelman; M A Vierra; A J Bastidas; J C Poen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-12-01       Impact factor: 7.038

8.  Intraoperative and external beam irradiation +/- 5-FU for locally advanced pancreatic cancer.

Authors:  L L Gunderson; J K Martin; L K Kvols; D M Nagorney; J M Fieck; H S Wieand; A Martinez; M J O'Connell; J D Earle; D C McIlrath
Journal:  Int J Radiat Oncol Biol Phys       Date:  1987-03       Impact factor: 7.038

9.  Intraoperative radiation therapy adjuvant to resection in the treatment of pancreatic cancer.

Authors:  A Zerbi; V Fossati; D Parolini; M Carlucci; G Balzano; G Bordogna; C Staudacher; V Di Carlo
Journal:  Cancer       Date:  1994-06-15       Impact factor: 6.860

10.  Radiosensitization of human tumor cells by gemcitabine in vitro.

Authors:  D S Shewach; T S Lawrence
Journal:  Semin Oncol       Date:  1995-08       Impact factor: 4.929

View more
  1 in total

1.  Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas.

Authors: 
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.